Taken together, these results strongly suggest that ZIL possesses higher biocompatibility than DMSO and has great potential for application in the life sciences
No randomized human trial has established a clinically validated dose all protocols derive from animal data and clinician case series, principally the Sikiric et al
That specificity also implies that choosing the right dose is important
Lipoprotein(a) and Atherogenesis Lipoprotein(a) [Lp(a)] was originally described as a new serum lipoprotein particle by Kare Berg in 1963
(Source) When this enzyme is present in great concentration within fat cells and is highly expressed, obesity is inevitable: In the study by Kannt and colleagues, NNMT expression is increased ~2-fold in subcutaneous and omental adipose tissue of type 2 diabetic subjects (men and women), compared to healthy controls Importantly, interventions that increase insulin sensitivity, such as exercise and bariatric surgery, also decreased expression of NNMT in adipose tissue For this reason alone, scientists have been interested in every possible method for inhibiting NNMT expression: We report that NNMT expression is increased in [white adipose tissue (WAT)] and liver of obese and diabetic mice
She just made it smarter